• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Pathophysiology of Pulmonary Arterial Hypertension

Opinion
Video

Panelists discuss how the pathophysiology of pulmonary arterial hypertension involves complex mechanisms across multiple genetic and treatment pathways, with over 20 identified genes and four major therapeutic targets including nitric oxide, endothelin, prostacyclin, and activin signaling inhibition.

Pathophysiology and Treatment Pathways

Pulmonary arterial hypertension (PAH) represents a complex disease with multifaceted pathophysiology involving over 20 identified genetic mutations that can contribute to disease development. The condition affects pulmonary vasculature and capillaries, causing narrowing that increases workload on the right ventricle and heart. Understanding these underlying mechanisms is crucial for effective disease management and treatment selection.

From a therapeutic perspective, PAH management has evolved to target four distinct treatment pathways, expanding from the traditional three-pathway approach. These pathways focus on nitric oxide signaling, endothelin receptor antagonism, prostacyclin pathway modulation, and the newer activin signaling inhibition. Each pathway offers unique mechanisms of action that can be leveraged individually or in combination to address the disease's complexity.

The multi-pathway approach to PAH treatment reflects the disease's heterogeneous nature and the need for personalized therapeutic strategies. By targeting different biological pathways simultaneously, clinicians can maximize treatment efficacy while addressing the various contributing factors to pulmonary vascular dysfunction. This comprehensive understanding of pathophysiology guides modern treatment algorithms and supports the development of innovative therapeutic approaches.

Related Videos
1 expert is featured in this series.
Eileen Peng, PharmD, sitting for a video interview
4 experts are featured in this series.
2 experts in this video
2 experts in this video
4 experts are featured in this series.
4 experts are featured in this series.
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.